Morgan Stanley
WINT

Morgan Stanley’s Windtree Therapeutics WINT Stock Holding History

Morgan Stanley’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,000
Closed -$18.9K – 8285
2025
Q1 		$18.9K Buy
+15,000
New +$92.5K ﹤0.01% 6591
2024
Q4 		– Sell
-74
Closed -$8.87K – 8106
2024
Q3 		$8.87K Buy
+74
New +$22.4K ﹤0.01% 6753
2024
Q1 		– Hold
0
– -$1 – 7977
2023
Q4 		– Hold
0
– – – 7813
2023
Q3 		– Hold
0
– – – 7591
2023
Q2 		– Hold
0
– – – 7646
2023
Q1 		– Hold
0
– – – 7684
2022
Q4 		– Hold
0
– – – 7826
2022
Q3 		– Hold
0
– – – 7893
2022
Q2 		– Hold
0
– – – 7992
2022
Q1 		– Hold
0
– – – 7694
2021
Q4 		– Hold
0
– – – 8123
2021
Q3 		– Hold
0
– – – 8033
2021
Q2 		– Hold
0
– – – 7808
2021
Q1 		– Hold
0
– – – 7576
2020
Q4 		– Hold
0
– – – 7124
2020
Q3 		– Hold
0
– – – 6836
2020
Q2 		– Hold
0
– – – 6732

Other funds holding WINT

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's WINT Position: Q2 2025 in Review

Morgan Stanley sold out of Windtree Therapeutics (WINT) in Q2 2025, closing a stake of 15,000 shares — an estimated $18.9K sold.

Morgan Stanley first reported a position in WINT in Q3 2024 and held it in 2 quarters. The position peaked at $18.9K in Q1 2025. 5 funds tracked by Wall St. Rank hold WINT as of Q2 2025.

  • Morgan Stanley reported no remaining Windtree Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 15,000 Windtree Therapeutics shares in Q2 2025, an estimated $18.9K.
  • Morgan Stanley first reported a position in Windtree Therapeutics in Q3 2024 and held it in 2 quarters.
  • Morgan Stanley's Windtree Therapeutics position peaked at $18.9K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.